Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Annovis Bio Inc (NY: ANVS )

9.650 +0.240 (+2.55%)
Official Closing Price Updated: 7:00 PM EDT, May 19, 2022 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 8,357
Open 9.110
Bid (Size) 9.750 (12)
Ask (Size) 10.00 (3)
Prev. Close 9.410
Today's Range 9.110 - 9.860
52wk Range 8.385 - 132.00
Shares Outstanding 8,163,923
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
Annovis Bio Announces First Quarter 2022 Results and Provides Corporate Update
Berwyn, Pennsylvania--(Newsfile Corp. - May 4, 2022) - Annovis Bio, Inc. (NYSE: ANVS) ("Annovis" or the "Company"), a clinical-stage drug... 
Via Newsfile
Benzinga's Top Ratings Upgrades, Downgrades For May 2, 2022
Upgrades 
Via Benzinga

Performance

YTD
-51.21%
-51.21%
1 Month
-25.19%
-25.19%
3 Month
-33.59%
-33.59%
6 Month
-64.14%
-64.14%
1 Year
-64.72%
-64.72%

More News

Read More
The Daily Biotech Pulse: FDA Approves Bristol Myers' Oral Heart Disease Drug, European Approval For Merck's Keytruda, Genocea Restructures, Zymeworks' Takeover Bid
Via Benzinga
Annovis Bio Announces Cooperative Research and Development Agreement (CRADA) with the National Institute on Aging
Via Newsfile
Annovis Bio to Participate in World Parkinson's Day to Raise Awareness on the Debilitating Disease
Via Newsfile
Annovis Bio to Present at the 2022 Virtual Growth Conference Presented by Maxim Group LLC and Hosted by M-Vest
Via Newsfile
Annovis Bio Presents at International Conference on Alzheimer's & Parkinson (AD/PD 2022)
Via Newsfile
Annovis Bio Announces Presentation at International Conference on Alzheimer's & Parkinson's Diseases 2022
Via Newsfile
Annovis Bio to Present at the Cowen 42nd Annual Health Care Conference
Via Newsfile
FDA Guides Annovis Bio For Two Phase 3 Buntanetap Trial In Parkinson's Disease
Via Benzinga
Annovis Bio Announces Positive FDA Feedback for Buntanetap Phase 3 Clinical Development in Parkinson's Disease
Via Newsfile
Exposures Product Safety
Annovis Bio Enhances Leadership Team with Two Senior Appointments
Via Newsfile
Annovis Bio Announces Official Unique Name Buntanetap for Lead Candidate ANVS401
Via Newsfile
Annovis Bio to Participate in the Biotech Showcase and H.C. Wainwright Bioconnect Virtual Conferences
Via Newsfile
12 Health Care Stocks Moving In Monday's After-Market Session
Via Benzinga
Annovis Bio on Its Positive Results in Alzheimer's and Parkinson's Clinical Trials
Via Benzinga
Annovis Bio CEO Maria Maccecchini Issues Letter to Stockholders
Via Newsfile
Annovis Bio Announces Publication of ANVS401 Mechanism of Action in Peer-Reviewed Pharmaceutics
Via Newsfile
12 Health Care Stocks Moving In Friday's After-Market Session
Via Benzinga
Annovis Bio Presented At The 14th Clinical Trials on Alzheimer's Disease Conference
Via Newsfile
Exposures Product Safety
The Daily Biotech Pulse: J&J To Spin-off Consumer Health Business, AstraZeneca Earnings, Embattled Emergent To Buy Back Shares
Via Benzinga
Annovis Bio Presents Poster on Mechanism of Action at the 14th Clinical Trials on Alzheimer's Disease (CTAD) Conference
Via Newsfile
The Daily Biotech Pulse: Double Dose Of Positive Tidings For Merck, Alkermes Slips On Partial Termination Of J&J Licensing Deal, Amgen Migraine Drug Data
Via Benzinga
The Week Ahead In Biotech (Nov. 7-Nov. 13): Earnings Taper Off, Multiple Conference Presentations, IPOs And More
Via Benzinga
92 Biggest Movers From Friday
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.